Earlier Tuesday, Endpoints News reported that former Stanford president Marc Tessier-Lavigne will lead one of biotech’s biggest-ever startup launches: Xaira Therapeutics, which has secured over $1 billion to transform drug discovery and development with AI.
The move is sure to raise eyebrows. Tessier-Lavigne resigned from his post at Stanford last summer after an intense investigation found evidence of falsified data in some of his old research papers. Although Tessier-Lavigne was cleared of wrongdoing himself, the panel critiqued his lab oversight and said he was too slow to correct or retract the bad data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.